MONTREAL, March 29, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a ...

Patients using Enerzair® and Atectura® Breezhaler® to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller’s digital health platform to help manage their condition.

Novartis NVS announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]).It was granted ...

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair ® Breezhaler ®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions ...

El Ministerio de Sanidad ha aprobado el precio y la financiación en el Sistema Nacional de Salud (SNS) de la combinación fija de acetato de indacaterol y furoato de mometasona de Novartis, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...

Patients in Japan using Enerzair® and Atectura® Breezhaler® to treat uncontrolled asthma will now have access to Propeller’s digital health platform through their clinician MADISON, Wis.--(BUSINESS ...